HEALTH TECHNOLOGY

HCL Technologies and NEORIS Sign Agreement for Integrated IT Services

HCL Technologies | March 23, 2022

HCL Technologies a leading global technology company, has signed a collaboration agreement with NEORIS, a leading global digital accelerator that co-creates disruptive solutions for digitally aspirational companies. The agreement will bring unique capabilities to clients in global markets, including the ability to increase application usage time, business management operations and integrated IT services.

As a result of this collaboration, both companies will be able to expand their operations and access new markets, making them better positioned to explore global markets. NEORIS, with more than 20 years of experience and global presence including operations in Latin America, will strengthen HCL’s presence in territories like Mexico and South America which offer great opportunities for commercial development. With operations in 52 countries, HCL Technologies will aid NEORIS in expanding its business internationally, primarily in the United States, Europe and Asia.

Together, NEORIS and HCL Technologies can speed up digital transformation, mitigate risks, empower teams based on product development, create a zero-incident culture and save costs. The solutions that NEORIS and HCL will offer together will focus on complementing approaches and solutions, new technologies and talent development among other areas of expertise.

 

"HCL Technologies and NEORIS will work together to find new business opportunities in a united effort, one where NEORIS will provide the best talent with the best skills in the market to reduce costs, time and risk. We have positioned our centers of excellence to scale and meet the expectations of each business and deliver value. Our partnership enables us to provide the best services and solutions to our clients while positioning them for future success."

Marcelo Costa, global head of strategic alliances at NEORIS

"We are delighted to offer this unique program to our clients in Latin America who are seeking ways to optimize their teams through best-in-class technology solutions," said Ajay Bahl, corporate vice president, HCL Technologies. "Our collaboration will also contribute to our continuous effort to build a great talent pool in Mexico to deliver industry-best service and capabilities to our customers."

About NEORIS

NEORIS is a leading global digital accelerator that co-creates disruptive solutions for companies that digitally aspire to increase their connections with customers, employees and stakeholders. The company is made of creative teams with technical experience and deep knowledge of their sectors. Headquartered in Miami, Florida, NEORIS has a network of global delivery centers, design studios, and operations in the United States, Europe, Latin America and India. More information is available at www.NEORIS.com, LinkedIn, and Twitter.

About HCL Technologies

HCL Technologies (HCL) empowers global enterprises with technology for the next decade, today. HCL’s Mode 1-2-3 strategy, based on its deep-domain industry expertise, customer-centricity and entrepreneurial culture of Ideapreneurship™, enables businesses to transform into next-gen enterprises.

HCL offers its services and products through three business units: IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in the areas of applications, infrastructure, digital process operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering

HCL Technologies (HCL) empowers global enterprises with technology for the next decade, today. HCL’s Mode 1-2-3 strategy, based on its deep-domain industry expertise, customer-centricity and entrepreneurial culture of Ideapreneurship™, enables businesses to transform into next-gen enterprises.

HCL offers its services and products through three business units: IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in the areas of applications, infrastructure, digital process operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering

Spotlight

Learn about the need of security that is unobtrusive and comprehensive, and that doesn't hinder clinical workflows or the delivery of care to patients.

Spotlight

Learn about the need of security that is unobtrusive and comprehensive, and that doesn't hinder clinical workflows or the delivery of care to patients.

Related News

HEALTH TECHNOLOGY

Exer Launches Gait and Physio Mobile Apps to Expand AI-Powered Digital Health Platform

Exer Labs | October 14, 2021

Exer Labs, an AI-powered digital health company committed to helping healthcare professionals leverage computer vision to modernize their assessments and treatment plans, has launched two new apps, Gait and Physio. Combined with previously launched apps Studio and Range of Motion, Exer now serves the needs of a diverse customer base as they upgrade their abilities to service the entire lifecycle of patients' needs remotely and in-person. Exer's suite of applications is powered by a custom, next-generation AI that runs on any device with a 2D camera (phone, tablet, laptops, etc). The software identifies specific biomarkers on the human body which provides health professionals and their patients with real-time data and summary metrics during exercises and functional movements. An intuitive user interface promotes engagement, adherence, and better long-term outcomes. Users simply open the app on their device, point the camera at the subject, and Exer's AI does the rest. Exer Gait is a rapid assessment app for gathering accurate gait metrics that helps qualified health professionals identify at-risk individuals and assess progress over time. Gait was initially conceived to address a growing health crisis in senior housing facilities around the world for which the pandemic has made assessments challenging but increasingly important to keeping residents healthy. The applications for an affordable, easy-to-use gait analysis tool didn't stop there, extending into workplace assessments, prosthetics, and professional athletics. "Our Gait app is analysis made easy. Whether you serve aging communities or professional athletes, we can help you generate usable, actionable gait data quickly and cost-effectively." Exer Founder and CEO Zaw Thet Salus Physical Therapy, an industry leader providing physical therapy and rehabilitation services for senior living facilities throughout the United States, is one of the first customers using Gait. Having seen what was possible utilizing Exer's motion intelligence software, the team at Salus provided valuable feedback and testing with Exer in clinical settings. The result, a simple tool that allows clinicians to take objective measurements that identify residents with an increased risk of adverse fall events and to provide feedback regarding progress. "Approximately half of the 1.6 million assisted-living residents in the U.S. fall while walking each year and just a slight decrease in gait speed can indicate a nearly 400% increase in the likelihood of a fall. Using Exer's Gait assessment app, our clinicians can identify potential problems before they happen and track progress over time. The measures we've taken to prevent falls, including Exer Gait, have helped us decrease the number of falls in our partner facilities by 60% this year." Salus CEO Nick Hughes Exer Physio is a digital physical therapy app that helps health professionals deliver high quality care both inside the clinic and remotely - dramatically extending their connection with patients. "Physio has been in development for two years and addresses a broader set of exercises and movements than anything else we've released." said Thet. "By helping PT's and physicians guide their patients through rehab in a more data-driven way and increasing the success of the rehab programs they offer, Physio fundamentally transforms the at-home physical therapy experience while making clinical visits more effective." Following in-clinic visits, PTs typically prescribe a series of relevant exercises or movements for patients to do at home between visits, and these home exercise protocols (HEPs) are the backbone of recovery plans. Physio provides therapists with a direct, data-driven connection to patients throughout the period of care by delivering verifiable metrics on these at-home exercises. For patients, the app is assessing and correcting exercise form in real-time and automatically counting reps, giving them confidence that they are doing their recovery protocol correctly. Inside Physio is an extensive library of more than 200 exercises from which a PT or physician can build their prescribed protocols - with more added each week. This motion library will eventually be opened up to customers, allowing them to add exercises or modifications that fit their needs. Cascade Sports Injury Prevention and Physical Therapy, a practice in Lakewood, Colo., is one of the clinics utilizing Physio and reported rave reviews from clients and provider partners alike. Physio has been an amazing addition to how we serve our patients and their rehabilitation needs," said Cascade Sports Founder Justin Dudley. "Each patient gets live form feedback, motivation and compliance tracking during home exercises. This allows our therapists to review progress with tangible and verifiable metrics to efficiently update the plan of care and maximize outcomes with each of our patients. It's incredible." Backed by top-tier venture capital and angel investors that include Signia Venture Partners, AME Cloud Ventures, Morado Ventures, Oceans Ventures, and Operator Partners, Exer is committed to helping the world move, train and play better.

Read More

HEALTH TECHNOLOGY

Mazars Introduces Mazars DataPath360 for Healthcare, the Company's First Microsoft IP Product

Mazars USA | April 20, 2021

Mazars, a leading audit, tax, and consulting company in the United States, is pleased to announce the launch of Mazars DataPath360 for Healthcare on Microsoft's App Store. This latest Mazars/Microsoft IP offering is the first in a series of industry-specific offerings that utilize the Microsoft Toolset, including Azure, Dynamics 365, RPA, and the Power Platform. Mazars DataPath360 architecture developed out of the Mazars Healthcare Consulting Practice, adding to their deep business experience and Microsoft expertise. Mazars DataPath360 for Healthcare provides companies with fast organizational support analytics and key insights to increase vendor efficiencies, optimize billing processes, boost financial outcomes, enrich the quality of care, and minimize risk. Mazars' Vendor Management module is the first in the corporation's lineup, and it includes a comprehensive range of report visualization techniques developed with Microsoft's Power BI and displayed directly in Microsoft Dynamics 365. Many of the improved features are available since Mazars DataPath360 is introduced as a native Dynamics 365 solution. Mazars DataPath360 for Healthcare tackles key vendor management and efficiency pain points specifically to enable Revenue Cycle enhancement across the lifecycle of patient service claims. Mazars DataPath360 uses automation to import data from clinical and financial processes, which is then combined with our analytics software to generate visual representations that easily summarise patterns in vendor management, contract monitoring, compliance and efficiency, and claim to invoice reconciliation. This enables healthcare professionals to analyze data and make better decisions. "Working with the Mazars Microsoft Practice team, headed by John Accardi, it became clear that Mazars is producing a large amount of unreleased IP globally and through a wide range of industry sectors. We are excited that this initial offering for healthcare professionals is getting momentum across the Microsoft ISV Connect platform and the Microsoft AppSource ecosystem. We are excited to collaborate with Mazars on additional IP and Services offerings "said John O'Donnell, Microsoft's Global Strategic ISV Alliance Manager – Biz Apps. About Mazars USA Mazars USA LLP is an independent member company of Mazars Group, a global audit, tax, and consulting firm with activities in over 90 countries. With origins in the United States dating back to 1921, the company has a strong global footprint in strategic geographies, allowing seamless access to 26,000+ professionals worldwide. Individuals, high-growth startup firms, privately-owned corporations, and major enterprises are among the customers served by the industry specialists.

Read More

HEALTH TECHNOLOGY

Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research

Invitae | September 07, 2021

Invitae, a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with the potential to drive research and improve healthcare decision making. "Invitae is relentlessly pursuing a day when genetics is used routinely to improve healthcare for billions of people around the globe. We believe combining Ciitizen's state-of-the-art, transparent and patient-consented platform with our technologies and services will accelerate our evolution into a genome information company that informs healthcare throughout one's life. This would give us the ability to engage patients, create an innovative patient-centered data ecosystem and deliver better outcomes for everyone. Invitae views the acquisition of Ciitizen as an important part of its strategy to be the industry leader across the genetic testing, software and health information technology spaces," said Sean George, Ph.D., co-founder and CEO of Invitae. "Ciitizen has already helped patients take ownership of their medical records to optimize therapy for themselves and contribute their data towards a variety of goals, including research on rare diseases," said Anil Sethi, CEO and founder of Ciitizen. "Patients leave a breadcrumb trail of records behind them, and we believe access to this real-world data is key to personalized therapeutics in the future. The combination of lifelong health history together with Invitae's world-class genetic and data services would enable a digital ecosystem of personalized services for each patient. Democratization of patient-consented data is expected to improve outcomes by providing access to third-parties for whom the patient has granted consent. Unlike many health data companies, we operate on the premise that it's the patient's data, not ours." Dr. George continued, "Genomics is currently a laboratory testing-based industry, but in the future it will look very much like an information industry. Developing an open-ended patient-centric platform of genomic, clinical and reported outcomes creates a thriving and purposeful network that truly advances healthcare. Patient control is the big differentiator at Ciitizen and at Invitae; and we believe combining forces is the right strategy for our businesses going forward." Empowering patients to combine their genomic and clinical information to improve clinical care Invitae is working to aggregate results from the world's genetic tests into a single, easy-to-use service that makes genetic information accessible to all who can benefit from it - always with patient consent. Over the past five years, Invitae has completed 13 acquisitions that have expanded its testing menu, lowered the cost of its tests, improved its customer experience and enhanced its ability to attract partners. Invitae raised more than $1.4 billion since the beginning of 2021, in part to identify and acquire key assets that bring the company closer to delivering on its vision. The addition of Ciitizen is expected to empower Invitae to more quickly extend its platform, adding a complementary patient service that streamlines the process of collecting and organizing health information from any source and uses machine learning to transform the unstructured (and largely untapped) health information to enable better care decisions, find clinical trials, and power research using real-world evidence. In addition, as the use of Invitae testing and the Ciitizen service expands, third-party access to consented genomic and other clinical data can be democratized to power a variety of applications that can enhance Invitae's business and growth strategy. Transaction Terms Under the terms of the agreement, Invitae will acquire Ciitizen for approximately $325 million (subject to adjustment), consisting of (i) approximately $125 million in cash and (ii) approximately 7,070,000 shares of Invitae common stock (based upon a trailing average closing price prior to the agreement date). Invitae will also issue approximately $225 million in restricted stock units (RSUs) to new employees who join Invitae in connection with its acquisition of Ciitizen. These RSUs will be granted under Invitae's 2015 Stock Incentive Plan, which is being amended and restated to increase a pool of shares of Invitae common stock thereunder which is used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08"). These RSUs have been approved by the Invitae Board of Directors and will be made as an inducement material to each employee entering into employment with Invitae in reliance on the employment inducement exemption under Rule 303A.08. These RSUs will cover up to a total of approximately 8,125,000 shares of Invitae common stock (based upon a trailing average closing price prior to the agreement date) and will vest in tranches of one-third upon each of the first, second and third anniversaries of the date of grant, subject to acceleration in the event of a termination without cause by Invitae or a termination with good reason by a recipient. A total of 99 recipients will receive these RSUs, and Anil Sethi, the CEO and founder of Ciitizen, will receive RSUs with respect to approximately 2,011,000 shares of Invitae common stock. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close this month. Conference Call and Webcast today at 8:30 a.m. ET / 5:30 a.m. PT Management will host a conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT to discuss the transaction. To register for the conference call, please use the link below. Upon registering, each participant will be provided with call details and a registrant ID. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae Corporation is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. About Ciitizen Ciitizen is a patient-centric consumer health technology platform that enables patients to collect, store and share their medical records in a single location. Ciitizen developed proprietary machine learning and AI technologies to abstract critical information from unstructured health records to advance the understanding of diseases, match patients with potentially life-saving clinical trials, and enable better care decisions. Ciitizen also provides valuable big data analytics and data quality technologies to the network of Health Information Exchanges (HIEs) to produce research-ready, regulatory-grade data within minutes, instead of hours or days, and ensure HIEs can comply with the Information Blocking regulations.

Read More